Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2796188 | Diabetes Research and Clinical Practice | 2015 | 5 Pages |
Abstract
•There is concern that incretin-based therapies may cause acute pancreatitis.•A prior meta-analysis of 55 small trials with just 37 events found no such effect.•Three recent large trials of DPP4 inhibitors included 80 acute pancreatitis events.•Pooling these trials showed a 82% increase in the odds of acute pancreatitis.•A significant effect remains when the prior 55 trials are added.
Previous studies have offered weak and conflicting evidence regarding the impact of incretin-based oral antihyperglycemic agents on risk of acute pancreatitis. This meta-analysis of three recent mega-trials found an 82% increase in the odds of acute pancreatitis with the use of these agents compared to usual care (95% CI, 1.17–2.82).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Pavel S. Roshanov, Brittany B. Dennis,